免疫功能受损癌症患者的脓毒性休克:叙述性综述
该叙述性综述聚焦免疫功能受损、尤其是癌症患者这一日益增长的人群,因其存在中性粒细胞减少、淋巴细胞减少及T、B细胞功能受损等多重免疫缺陷,叠加糖皮质激素、细胞毒药物、免疫治疗及黏膜损伤、留置导管等保护屏障破坏,脓毒症与脓毒性休克风险升高。进展为脓毒性休克的危险因素包括高龄、基础合并症、衰弱、癌症类型、免疫抑制程度、低白蛋白血症、低磷血症、革兰阴性菌血症及初始治疗反应的类型与时机。临床实践偏倚可导致转入ICU延迟和结局更差;尽管脓毒性休克在恶性肿瘤患者中通常预后不良,但生存率随时间显著改善。作者认为,通过整合无线技术、医学信息学、精准医学等创新技术、靶向管理策略及包括早期识别诊断和及时转入高级别多学科监护的稳健临床实践,对改善预后至关重要。
要点
- 免疫功能受损癌症患者脓毒性休克风险升高,与中性粒细胞减少、淋巴细胞减少、T和B细胞功能受损等多重免疫缺陷有关。
- 进展为脓毒性休克的危险因素包括高龄、基础合并症、衰弱、癌症类型、免疫抑制程度、低白蛋白血症、低磷血症、革兰阴性菌血症及初始治疗反应类型与时机。
- 临床实践偏倚可能导致转入重症监护延迟并造成更差结局。
- 脓毒性休克在恶性肿瘤患者中通常预后不良,但生存率随时间显著改善。
- 作者认为需通过整合创新技术、靶向管理策略及早期识别诊断、及时转入高级别多学科监护来改善预后。
适用人群与场景
- 免疫功能受损的癌症患者,尤其存在中性粒细胞减少、淋巴细胞减少、T和B细胞功能受损者。
- 同时使用免疫抑制治疗(如糖皮质激素、细胞毒药物、免疫治疗)及存在天然保护屏障破坏(如黏膜损伤、慢性留置导管、解剖结构改变)者。
研究设计与关键结果
- 叙述性综述指出,免疫抑制癌症患者因多重免疫缺陷及免疫抑制治疗、保护屏障破坏而感染风险升高。
- 进展为脓毒性休克的危险因素包括高龄、基础合并症、衰弱、癌症类型、免疫抑制程度、低白蛋白血症、低磷血症、革兰阴性菌血症及初始治疗反应的类型与时机。
- 临床实践偏倚可能导致转入重症监护延迟和更差结局。
- 脓毒性休克在恶性肿瘤患者中通常预后不良,但生存率随时间显著改善。
证据类型、等级与局限
- 证据类型:叙述性综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需通过整合无线技术、医学信息学、精准医学等创新技术、靶向管理策略及包括早期识别诊断和及时转入高级别多学科监护的稳健临床实践,以改善免疫功能受损癌症脓毒性休克患者的预后和总生存率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Immunosuppressed patients, particularly those with cancer, represent a momentous and increasing portion of the population, especially as cancer incidence rises with population growth and aging. These patients are at a heightened risk of developing severe infections, including sepsis and septic shock, due to multiple immunologic defects such as neutropenia, lymphopenia, and T and B-cell impairment. The diverse and complex nature of these immunologic profiles, compounded by the concomitant use of immunosuppressive therapies (e.g., corticosteroids, cytotoxic drugs, and immunotherapy), superimposed by the breakage of natural protective barriers (e.g., mucosal damage, chronic indwelling catheters, and alterations of anatomical structures), increases the risk of various infections. These and other conditions that mimic sepsis pose substantial diagnostic and therapeutic challenges. Factors that elevate the risk of progression to septic shock in these patients include advanced age, pre-existing comorbidities, frailty, type of cancer, the severity of immunosuppression, hypoalbuminemia, hypophosphatemia, Gram-negative bacteremia, and type and timing of responses to initial treatment. The management of vulnerable cancer patients with sepsis or septic shock varies due to biased clinical practices that may result in delayed access to intensive care and worse outcomes. While septic shock is typically associated with poor outcomes in patients with malignancies, survival has significantly improved over time. Therefore, understanding and addressing the unique needs of cancer patients through a new paradigm, which includes the integration of innovative technologies into our healthcare system (e.g., wireless technologies, medical informatics, precision medicine), targeted management strategies, and robust clinical practices, including early identification and diagnosis, coupled with prompt admission to high-level care facilities that promote a multidisciplinary approach, is crucial for improving their prognosis and overall survival rates.
参考来源
- Nates JL, Pène F, Darmon M, et al. Septic shock in the immunocompromised cancer patient: a narrative review. Crit Care. 2024. PMID: 39215292. doi:10.1186/s13054-024-05073-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。